Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses

Antiviral Research

Volumn 126, Issue , 2016, Pages 62-68

  Westover, Jonna B ^a   Sefing, Eric J ^a   Bailey, Kevin W ^a   Van Wettere, Arnaud J ^a,b   Jung, Kie Hoon ^a   Dagley, Ashley ^a   Wandersee, Luci ^a   Downs, Brittney ^a   Smee, Donald F ^a   Furuta, Yousuke ^c   Bray, Mike ^d   Gowen, Brian B ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b Utah Veterinary Diagnostic Laboratory   (United States)

^c TOYAMA CHEMICAL CO LTD   (Japan)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Arenavirus; Favipiravir; Junin virus; Ribavirin; Viral hemorrhagic fever

Indexed keywords

AMIDE; ANTIVIRUS AGENT; FAVIPIRAVIR; PYRAZINE DERIVATIVE; RIBAVIRIN;

ANIMAL; ARENAVIRUS; BLOOD; CHLOROCEBUS AETHIOPS; DENGUE VIRUS; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GUINEA PIG; HAMSTER; HANTAVIRUS; HEMORRHAGIC FEVER, AMERICAN; HEMORRHAGIC FEVER, EBOLA; HEMORRHAGIC FEVERS, VIRAL; JUNIN VIRUS; MALE; MESOCRICETUS; MOUSE; NAIROVIRUS; RNA VIRUS; VERO CELL LINE; VETERINARY; VIROLOGY;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; ARENAVIRUS; CERCOPITHECUS AETHIOPS; CRICETINAE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; GUINEA PIGS; HANTAVIRUS; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, AMERICAN; HEMORRHAGIC FEVER, EBOLA; HEMORRHAGIC FEVERS, VIRAL; JUNIN VIRUS; MALE; MESOCRICETUS; MICE; PYRAZINES; RIBAVIRIN; RNA VIRUSES; VERO CELLS;

EID: 84952917995     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.12.006     Document Type: Article

References (23)

1. H.C. Bodenheimer Jr., K.L. Lindsay, G.L. Davis, J.H. Lewis, S.N. Thung, and L.B. Seeff Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial Hepatology 26 1997 473 477
2. L. Borio, T. Inglesby, C.J. Peters, A.L. Schmaljohn, J.M. Hughes, P.B. Jahrling, T. Ksiazek, K.M. Johnson, A. Meyerhoff, T. O'Toole, M.S. Ascher, J. Bartlett, J.G. Breman, E.M.J. Eitzen, M. Hamburg, J. Hauer, D.A. Henderson, R.T. Johnson, G. Kwik, M. Layton, S. Lillibridge, G.J. Nabel, M.T. Osterholm, T.M. Perl, P. Russell, K. Tonat, and o.t.W.G.o.C. Biodefense Hemorrhagic fever viruses as biological weapons: medical and public health management JAMA 287 2002 2391 2405
3. L.E. Chapman, G.J. Mertz, C.J. Peters, H.M. Jolson, A.S. Khan, T.G. Ksiazek, F.T. Koster, K.F. Baum, P.E. Rollin, A.T. Pavia, R.C. Holman, J.C. Christenson, P.J. Rubin, R.E. Behrman, L.J. Bell, G.L. Simpson, and R.F. Sadek Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group Antivir. Ther. 4 1999 211 219
4. L. Delang, N. Segura Guerrero, A. Tas, G. Querat, B. Pastorino, M. Froeyen, K. Dallmeier, D. Jochmans, P. Herdewijn, F. Bello, E.J. Snijder, X. de Lamballerie, B. Martina, J. Neyts, M.J. van Hemert, and P. Leyssen Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral J. Antimicrob. Chemother. 69 2014 2770 2784
5. S.F. Emonet, A.V. Seregin, N.E. Yun, A.L. Poussard, A.G. Walker, J.C. de la Torre, and S. Paessler Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease J. Virol. 85 2011 1473 1483
6. D.A. Enria, and J.I. Maiztegui Antiviral treatment of Argentine hemorrhagic fever Antivir. Res. 23 1994 23 31
7. Y. Furuta, B.B. Gowen, K. Takahashi, K. Shiraki, D.F. Smee, and D.L. Barnard Favipiravir (T-705), a novel viral RNA polymerase inhibitor Antivir. Res. 100 2013 446 454
8. Y. Furuta, K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, N. Nomura, H. Egawa, and K. Shiraki Mechanism of action of T-705 against influenza virus Antimicrob. Agents Chemother. 49 2005 981 986
9. B.B. Gowen, T.L. Juelich, E.J. Sefing, T. Brasel, J.K. Smith, L. Zhang, B. Tigabu, T.E. Hill, T. Yun, C. Pietzsch, Y. Furuta, and A.N. Freiberg Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever PLoS Negl. Trop. Dis. 7 2013 e2614
10. B.B. Gowen, D.F. Smee, M.H. Wong, J.O. Hall, K.H. Jung, K.W. Bailey, J.R. Stevens, Y. Furuta, and J.D. Morrey Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin PLoS One 3 2008 e3725
11. B.B. Gowen, M.H. Wong, K.H. Jung, A.B. Sanders, M. Mendenhall, K.W. Bailey, Y. Furuta, and R.W. Sidwell In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections Antimicrob. Agents Chemother. 51 2007 3168 3176
12. J.D. Graci, and C.E. Cameron Mechanisms of action of ribavirin against distinct viruses Rev. Med. Virol. 16 2006 37 48
13. Y. Hitomi, E.T. Cirulli, J. Fellay, J.G. McHutchison, A.J. Thompson, C.E. Gumbs, K.V. Shianna, T.J. Urban, and D.B. Goldstein Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function Gastroenterology 140 2011 1314 1321
14. N.A. Ilyushina, A. Hay, N. Yilmaz, A.C. Boon, R.G. Webster, and E.A. Govorkova Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice Antimicrob. Agents Chemother. 52 2008 3889 3897
15. D.M. Kochhar, J.D. Penner, and T.B. Knudsen Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice Toxicol. Appl. Pharmacol. 52 1980 99 112
16. M. Mendenhall, A. Russell, D.F. Smee, J.O. Hall, R. Skirpstunas, Y. Furuta, and B.B. Gowen Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever PLoS Negl. Trop. Dis. 5 2011 e1342
17. L. Oestereich, T. Rieger, M. Neumann, C. Bernreuther, M. Lehmann, S. Krasemann, S. Wurr, P. Emmerich, X. de Lamballerie, S. Olschlager, and S. Gunther Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever PLoS Negl. Trop. Dis. 8 2014 e2804
18. M.N. Prichard, and C.J. Shipman A three-dimensional model to analyze drug-drug interactions Antivir. Res. 14 1990 181 205
19. L.J. Reed, and H. Muench A simple method of estimating fifty percent endpoints Am. J. Hyg. 27 1938 493 497
20. D. Safronetz, D. Falzarano, D.P. Scott, Y. Furuta, H. Feldmann, and B.B. Gowen Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome Antimicrob. Agents Chemother. 57 2013 4673 4680
21. D. Scharton, K.W. Bailey, Z. Vest, J.B. Westover, Y. Kumaki, A. Van Wettere, Y. Furuta, and B.B. Gowen Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment Antivir. Res. 104 2014 84 92
22. M. Schibler, P. Vetter, P. Cherpillod, T.J. Petty, S. Cordey, G. Vieille, S. Yerly, C.A. Siegrist, K. Samii, J.A. Dayer, M. Docquier, E.M. Zdobnov, A.J. Simpson, P.S. Rees, F.B. Sarria, Y. Gasche, F. Chappuis, A. Iten, D. Pittet, J. Pugin, and L. Kaiser Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report Lancet 15 2015 1034 1040
23. S.J. Smither, L.S. Eastaugh, J.A. Steward, M. Nelson, R.P. Lenk, and M.S. Lever Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model Antivir. Res. 104 2014 153 155